A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC - Trial NCT06328049
Access comprehensive clinical trial information for NCT06328049 through Pure Global AI's free database. This Phase 2 trial is sponsored by Taixing People's Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Taixing People's Hospital
Timeline & Enrollment
Phase 2
Aug 10, 2023
Aug 10, 2025
Primary Outcome
Incidence of febrile neutropenia (FN)
Summary
The aim of this study is to investigate the safety and efficacy of the prophylactic use of
 Trilaciclib in patients with non-small cell lung cancer (NSCLC) receiving platinum-based
 chemotherapy, so as to provide more evidence-based medical evidence for the optimal diagnosis
 and treatment strategy in this population.
Data Source
ClinicalTrials.gov
NCT06328049
Non-Device Trial